From: Warfarin and fibrinolysis - a challenging combination: an observational cohort study
ICH or major bleeding, n = 7 | Minor bleeding, n = 7 | No bleeding, n = 22 | |
---|---|---|---|
Age (years)* | 69 (63-72) | 67 (61-78) | 70 (62-79) |
Sex; men | 7 (100%) | 5 (70%) | 16 (73%) |
Earlier fibrinolysis | 0 | 3 (43%) | 6 (27%) |
Contraindication for fibrinolysis (other than warfarin) | 1 (14%) | 0 | 3 (18%) |
Systolic BP* | 126 (105-141) | 127 (90-140) | 122 (111-140) |
Diastolic BP* | 64 (61-92) | 69 (60-81) | 76 (70-90) |
Fibrinolytic agent | |||
streptokinase | 1 (14.3%) | 0 | 5 (23%) |
tPA (alteplase) | 1 (14.3%) | 1 (14.3%) | 1 (4.5%) |
reteplase | 5 (71.4%) | 5 (71.4%) | 13 (59%) |
tenecteplase | 0 | 1 (14.3%) | 3 (13.5%) |
Adjuvant medication | |||
aspirin | 1 (14%) | 3 (43%) | 15 (68%) |
heparin | 5 (71%) | 5 (71%) | 14 (64%) |
UFH | 3 (43%) | 1 (14%) | 2 (9%) |
LMWH | 2 (29%) | 4 (57%) | 12 (55%) |
LMWH (i.v.+s.c.) | 1 (14%) | 2 (29%) | 3 (14%) |
LMWH only i.v. | 1 (14%) | 2 (29%) | 6 (27%) |
LMWH reduced dose s.c | 0 | 0 | 3 (14%) |
Laboratory parameters at hospital arrival | |||
thrombocytes (x109/l)* | 168 (144-191) | 205 (165-227) | 161 (134-188) |
haemoglobin (g/l)* | 153 (133-163) | 145 (139-155) | 136 (125-141) |
Survival | |||
hospital discharge | 5 (71%) | 5 (71%) | 16 (73%) |
30 days | 5 (71%) | 5 (71%) | 14 (64%) |
1 year | 5 (71%) | 4 (57%) | 13 (59%) |